XT
OTLK icon

XTX Topco’s Outlook Therapeutics OTLK Stock Holding History

XTX Topco’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,994
Closed -$10.9K – 4561
2026
Q1 		$10.9K Buy
52,994
+22,770
+75% +$9.84K ﹤0.01% 3671
2025
Q4 		$47.8K Buy
30,224
+19,214
+175% +$30.7K ﹤0.01% 2844
2025
Q3 		$11.7K Sell
11,010
-72,140
-87% -$125K ﹤0.01% 2423
2025
Q2 		$133K Buy
+83,150
New +$133K 0.01% 1818
2025
Q1 		– Sell
-10,244
Closed -$19.4K – 2915
2024
Q4 		$19.4K Sell
10,244
-27,084
-73% -$111K ﹤0.01% 2047
2024
Q3 		$199K Buy
+37,328
New +$273K 0.01% 1445
2022
Q2 		– Sell
-2,105
Closed -$75K – 1037
2022
Q1 		$75K Buy
+2,105
New +$65.7K 0.03% 551
2021
Q3 		– Sell
-544
Closed -$27K – 963
2021
Q2 		$27K Buy
+544
New +$25.2K 0.01% 756

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

XTX Topco's OTLK Position: Q2 2026 in Review

XTX Topco sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 52,994 shares — an estimated $10.9K sold.

XTX Topco first reported a position in OTLK in Q2 2021 and held it in 8 quarters. The position peaked at $199K in Q3 2024. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • XTX Topco reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 52,994 Outlook Therapeutics shares in Q2 2026, an estimated $10.9K.
  • XTX Topco first reported a position in Outlook Therapeutics in Q2 2021 and held it in 8 quarters.
  • XTX Topco's Outlook Therapeutics position peaked at $199K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.